FILE 01 / EVIDENCE REVIEW
BPC-157: what the evidence actually shows (and doesn’t)
Prepared by: Research Desk. Sources are linked for verification.
Status: Not approved. BPC-157 is not FDA-approved for any use. It is prohibited at all times under the WADA anti-doping code. See our legal status file.
Contents
BPC-157 is the most-searched peptide in the United States. Forums, podcasts and online marketing describe it as a near-miraculous compound for tendons, guts and joints. The aim of this guide is narrow and unglamorous: to set out what has actually been tested, in what, and with what result. The short version is that the animal literature is large and mostly positive. The human literature consists of three small, uncontrolled reports, and there is no clinical safety data.
What BPC-157 is
BPC stands for “body protection compound”. BPC-157 is a synthetic chain of 15 amino acids (a pentadecapeptide). It is described as derived from a protein found in human gastric juice [1]. Most of the early research came from one research group in Croatia, which explains its original focus on the stomach and gut. Its supporters call it “naturally occurring”, but the molecule used in research and sold online is synthetic. Independent replication outside that original group remains limited, and that’s worth keeping in mind as you read the rest of this page.
How it is proposed to work
Systematic reviews summarise preclinical findings suggesting that BPC-157 [1]:
increases expression of growth hormone receptors in tendon cells;
activates pathways involved in cell growth and angiogenesis (new blood vessel formation);
reduces inflammatory cytokines.
Each of these comes from cell or animal work. Even taken together, they don’t predict what will happen in a person. Angiogenesis, in particular, is a double-edged mechanism: it is part of normal tissue repair, but it also supports tumour growth. That’s one reason long-term human safety data matter.
The animal evidence: large and mostly positive
In 2025, Vasireddi and colleagues published a systematic review of BPC-157 in orthopaedic sports medicine. It screened 544 articles published from 1993 to 2024 and included 36 studies. Thirty-five were preclinical and one was clinical [1]. In the preclinical models, researchers reported improved functional, structural and biomechanical outcomes in muscle, tendon, ligament and bone injuries [1]. Preclinical safety studies reported no adverse effects across several organ systems [1].
Why the animal data don’t settle it:
Rodents aren’t people. Tissue-repair rates, tissue biology and dose scaling differ substantially.
Concentration of authorship. When most positive results come from a small number of labs, independent replication is essential.
Publication bias. Negative animal studies are less likely to be published.
Formulation. Many experiments used preparations that differ from products sold online.
The human evidence: three small reports
Here is the complete human evidence base we could find in the peer-reviewed literature.
Report 1: knee pain, retrospective (2021)
A retrospective chart review from a Florida practice covered people who had received BPC-157 for knee pain, alone or with thymosin β-4. Of 16 people reached by phone, 12 had received BPC-157 alone, and 11 of those reported significant improvement in knee pain [2].
Problems:
It was retrospective.
There was no control group.
Pain was rated by telephone recall, months after the procedure.
“No specific tools” were used to measure function or quality of life [2].
Participants had many different causes of knee pain.
Even the summary figures vary between sources. The 2025 systematic review describes the same literature as 7 of 12 people reporting relief for more than 6 months [1]. The original paper reports 11 of 12 with “significant improvement” [2]. The difference probably reflects different definitions, such as how long the relief lasted. Either way, it’s a reminder of how soft this evidence is.
Report 2: two-person safety pilot (2025)
Two participants with prior BPC-157 exposure received the compound on two days in a small pilot. Blood markers of heart, liver, kidney, thyroid and glucose function showed no measurable changes, and no side effects were reported [3].
Problems: There were only two people, it lasted three days, and the participants were self-selected and already exposed. The authors’ conclusion that the results “showed the safety of BPC-157 in humans” [3] goes far beyond what two participants over three days can show.
Report 3: the 2026 systematic review of human evidence
In 2026, Poolton and colleagues published a PRISMA-compliant systematic review restricted to human studies of BPC-157. They searched databases and ClinicalTrials.gov up to June 2026 and found three studies with 30 participants in total: the knee-pain series, a pilot in interstitial cystitis, and the two-person safety pilot [4]. All were judged to be of poor methodological quality. Overall certainty of evidence was rated very low. The authors concluded that BPC-157 “should not be used clinically in humans outside ethically approved, regulated, high-quality clinical trials” [4].
That’s the most up-to-date independent assessment we know of, and we agree with it.
Claims, rated
Claim
Best evidence
Our rating
Gut lining / ulcerative colitis
Animal studies; FDA advisory review of the UC use in July 2026
Unproven in humans
“Systemic repair”, anti-aging, brain effects
Animal or speculative
Unsupported
Side effects and safety
What we know: almost nothing from controlled human studies. The 2025 systematic review found no clinical safety data [1].
What we can reasonably say:
Short half-life. BPC-157 is reported to have a half-life of less than 30 minutes. It is metabolised in the liver and cleared by the kidneys [1].
Product quality is the biggest practical risk. The 2025 review warns that adverse effects are possible “due to unregulated manufacturing, contamination, or unknown clinical safety” [1]. FDA has documented concerns about immunogenicity (immune reactions to the peptide or its impurities) and about difficulty characterising the active ingredient [5].
Sterility risks. Non-sterile products carry risks of infection and abscess.
Theoretical long-term concerns. Because BPC-157 promotes angiogenesis in animal models [1], researchers have raised questions about tumour growth. These are unstudied in humans.
In the U.S., adverse reactions can be reported to FDA MedWatch [6].
BPC-157 vs TB-500
TB-500 is a synthetic fragment related to thymosin β-4. It is often marketed alongside BPC-157 as a “recovery stack”. The honest comparison:
Evidence: Both rest mainly on animal research. The human literature for both is minimal; the knee series is one of the few reports to include thymosin β-4 [2].
Regulatory: Both were on the agenda of FDA’s 23 July 2026 compounding advisory committee, BPC-157 for ulcerative colitis and TB-500 for wound healing. Both are prohibited by WADA (see our legal status page).
Combination: There is no controlled evidence that combining them does anything beyond what either does alone.
What would change our minds
We’d update this guide significantly if any of the following appeared:
a registered, randomized, placebo-controlled human trial with objective outcomes (imaging, validated function scores);
independent pharmacokinetic and safety studies;
an FDA decision listing BPC-157 for a specific compounded use, with the evidence FDA relied on.
Bottom line
BPC-157 is a scientifically interesting peptide with a large, mostly positive animal literature. Its human evidence base consists of 30 people across three poor-quality studies [4]. It is not an approved drug, it is banned in tested sport, and the products sold online are of unknown quality. Interesting is not the same as proven.
How to read a BPC-157 claim online
When a confident claim about BPC-157 appears, it can be run through these five questions:
Which species? If the study was in rats, the claim is about rats. Almost all of the efficacy literature is preclinical [1].
Was there a control group? None of the three human reports had a randomized placebo control [4].
How many people? Thirty, across all published human studies combined [4].
Who is making the claim, and do they sell something? Sellers and service providers have a financial interest.
Does the claim mention regulatory status? A source that doesn’t mention FDA’s concerns [5] or the WADA ban isn’t giving you the full picture.
A claim that fails three or more of these isn’t evidence. It’s marketing.
Last updated: 18 October 2026.
Not medical advice. This page reports published research and regulatory records for information only.